Delpor doses first patient in once-yearly risperidone implant trial

The DLP-114 implant [image from Delpor]Delpor announced today that it dosed the first patient in a Phase 1b/2a clinical trial for its DLP-114 risperidone implant.

DLP-114 is a long-acting formulation of the antipsychotic risperidone for schizophrenia maintenance therapy. The open-label study is to evaluate the safety, tolerability and pharmacokinetics of switching from oral risperidone to the once- or twice-yearly DLP-114 risperidone implant, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0